Presentation is loading. Please wait.

Presentation is loading. Please wait.

Progesterone receptor

Published byMagnus Atkins Modified over 6 years ago

Similar presentations

Presentation on theme: "Progesterone receptor"— Presentation transcript:

1 Progesterone receptor
Figure S1 A 231 SKBr3 Mcf-7 ZR75 B -130 kda Progesterone Receptor -100 kda -70 kda Estrogen Receptor Progesterone receptor Actin -55 kda Mcl-1 Actin -35 kda MCF-7

2 Figure S2 Fold increase Fold increase SKBr3 cells MDA-MB 231 cells

3 Fold increase in luciferase activity
Figure S3 Fold increase in luciferase activity

4 Supplemental Figure S4 Input positive control for ChIP Negative control for ChIP No treatment E2 treatment, 6 hours No template control + -

5 Supplemental Figure S5 Figure 12

Download ppt "Progesterone receptor"

Similar presentations

Supplemental Figure 1 a % pulldown from input LNCaP/scrambled-siRNA Figure 1 A, ChIP analysis of AR and PHB binding to the PSA promoter in the LNCaP/scrambled-siRNA.

Supplemental Figure 1 a % pulldown from input LNCaP/scrambled-siRNA Figure 1 A, ChIP analysis of AR and PHB binding to the PSA promoter in the LNCaP/scrambled-siRNA.
Supplementary Figure 1 Supplemental Figure 1. Nogin siRNA potentiates BMP2-induced Smad-dependent BMP- signaling MDA-MB-231 breast cancer cells. MDA-MB-231/BREluc.

Supplementary Figure 1 Supplemental Figure 1. Nogin siRNA potentiates BMP2-induced Smad-dependent BMP- signaling MDA-MB-231 breast cancer cells. MDA-MB-231/BREluc.
Supplemental Figure 1 A No. at risk T3 530 483 304 185 50 T2 559 545 373 228 76 T1 540 532 375 208 64.

Supplemental Figure 1 A No. at risk T T T
Duong et al Figure 1 A InputsGST-Mdm2 HEGO HE11HE19HE15 HEGO HE11 HE19HE15 B HEGO A/BCEFD 1595 HE11 A/BEFD CEFD HE19 A/BC HE15 C D ER  I GST-Mdm2GST C.

Duong et al Figure 1 A InputsGST-Mdm2 HEGO HE11HE19HE15 HEGO HE11 HE19HE15 B HEGO A/BCEFD 1595 HE11 A/BEFD CEFD HE19 A/BC HE15 C D ER  I GST-Mdm2GST C.
Supplemental Figure 1: Chemical structures of fludioxonil and fenhexamid. FludioxonilFenhexamid.

Supplemental Figure 1: Chemical structures of fludioxonil and fenhexamid. FludioxonilFenhexamid.
Figure S1 A P

Figure S1 A P
Knight et al – Supplementary Table Supplemental Table 1: Cell line Densitometry AROSSIRT1 ARPE1965.810.7 WI380.131.9 MCF10A16.751.9 HCT116115.3177.6 HCT116.

Knight et al – Supplementary Table Supplemental Table 1: Cell line Densitometry AROSSIRT1 ARPE WI MCF10A HCT HCT116.
P247. Figure 9-1 p248 Figure 9-2 p251 p251 Figure 9-3 p253.

P247. Figure 9-1 p248 Figure 9-2 p251 p251 Figure 9-3 p253.
Mandal CC et al Supplementary Fig. S1. Increased expression of CSF-1 in human breast cancer cells. (A) The conditioned media from normal human breast epithelial.

Mandal CC et al Supplementary Fig. S1. Increased expression of CSF-1 in human breast cancer cells. (A) The conditioned media from normal human breast epithelial.
Figure 1. Figure 2 ab p=0.0009 p=0.0014 *** Figure 3 a *** b cFos TP53 Beta actin cFos TP53 Beta actin.

Figure 1. Figure 2 ab p= p= *** Figure 3 a *** b cFos TP53 Beta actin cFos TP53 Beta actin.
Fig S1 Relative mRNA expression MCF7 pS2 * * * * * CCNG2 * * * * * * RPRM * * * * KLF6 * * * * * * CLDN4 * * * CERK * * * EFEMP1 * * * ENC1 * * BIK * *

Fig S1 Relative mRNA expression MCF7 pS2 * * * * * CCNG2 * * * * * * RPRM * * * * KLF6 * * * * * * CLDN4 * * * CERK * * * EFEMP1 * * * ENC1 * * BIK * *
Supplemental Figure S1: Diagram to show previously reported interactions between EGFR and 23 other Egr1 target genes using Pathway Studio, Ariadne Inc.

Supplemental Figure S1: Diagram to show previously reported interactions between EGFR and 23 other Egr1 target genes using Pathway Studio, Ariadne Inc.
Supplemental Figure S1 A B MDA-MB-231 MCF-7 BCL-2MDA-MB-231 BCL-2 MCF-7 Bcl-2 Actin Bcl-2 Actin.

Supplemental Figure S1 A B MDA-MB-231 MCF-7 BCL-2MDA-MB-231 BCL-2 MCF-7 Bcl-2 Actin Bcl-2 Actin.
Figure1 HER2 SKBr3 PC3 A. SKBr3 cells Figure1 0 0.03 0.3 3 30 (µM) 120 100 80 60 40 20 0 Penetratin control % of control 0 0.03 0.3 3 30 (µM) 120 100.

Figure1 HER2 SKBr3 PC3 A. SKBr3 cells Figure (µM) Penetratin control % of control (µM)
Supplementary Figure S1 a

Supplementary Figure S1 a
Figure 6. Effect of Withaferin A (WA) treatment on leptin-induced signaling in breast cancer cells. A) Immunoblotting for pSTAT3 (Tyr705), total STAT3,

Figure 6. Effect of Withaferin A (WA) treatment on leptin-induced signaling in breast cancer cells. A) Immunoblotting for pSTAT3 (Tyr705), total STAT3,
* Supplementary Figure 1: Treatment of siramesine with various chemotherapeutic drugs in MDA MB 231 cells. MDA MB 231 cells were treated with 10μM siramesine.

* Supplementary Figure 1: Treatment of siramesine with various chemotherapeutic drugs in MDA MB 231 cells. MDA MB 231 cells were treated with 10μM siramesine.
Figure 3. Synergistic effects of the combination of trabectedin and olaparib on poly(ADP-ribosyl)ation and DNA damage in four different breast cancer cell.

Figure 3. Synergistic effects of the combination of trabectedin and olaparib on poly(ADP-ribosyl)ation and DNA damage in four different breast cancer cell.
Supplemental Material

Supplemental Material
A Western Blot B Colony Scattering Assay VEC ARTN siCONT siARTN VEC

A Western Blot B Colony Scattering Assay VEC ARTN siCONT siARTN VEC

Similar presentations

Ads by Google